12 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 12 of 12 clinical reviews.
A clinical guide for adolescents aged 12 to 17 taking flibanserin (Addyi) as they transition to adult care, covering FDA status, safety monitoring, alcohol restrictions, and what to expect from providers.
Flibanserin (Addyi) is FDA-approved only for premenopausal adults. This clinical guide covers the evidence gaps, safety concerns, and regulatory context for any off-label consideration in adolescents ages 12 to 17.
A clinical review of flibanserin (Addyi) use in geriatric patients aged 65 and older, covering pharmacokinetics, safety signals, drug interactions, and what the evidence actually shows for this age group.
A clinical guide to flibanserin (Addyi) use in geriatric patients aged 65 and older, covering cognitive effects, fall risk, driving, physical activity, and how to stay safe during daily routines.
A clinician-reviewed guide to flibanserin use in patients aged 65 and older, covering off-label status, pharmacokinetics, drug interactions, hypotension risk, and what the evidence does and does not support.
A clinician-reviewed guide to flibanserin (Addyi) use in geriatric patients aged 65 and older, covering pharmacokinetics, safety, alcohol interaction, dose management, and transition-of-care planning for women moving from reproductive to post-reproductive care.
A clinical review of flibanserin (Addyi) exposure in pediatric patients under age 12, covering accidental ingestion risks, CNS developmental concerns, and evidence-based management guidance.
Flibanserin (Addyi) is FDA-approved only for premenopausal adult women. This clinical review explains why off-label use in children under 12 is not supported by evidence, what the known pharmacology means for a developing brain, and how clinicians should respond to inquiries.
Flibanserin (Addyi) is not approved for children under 12. This clinical guide explains the FDA approval scope, CNS sedation risks relevant to school performance, and what parents and clinicians should know about activity restrictions.
Flibanserin (Addyi) is FDA-approved only for premenopausal adult women. This clinical guide explains why it has no role in children under 12, how to manage the transition to adult care, and what providers and families need to know.
Complete caregiver guide to administering flibanserin (Addyi) in adolescents aged 12-17: FDA approval status, dosing, alcohol restrictions, drug interactions, and safety monitoring.
Evidence-based guidance for caregivers administering flibanserin (Addyi) to patients aged 65 and older, covering dose, timing, alcohol restrictions, fall risk, drug interactions, and monitoring protocols.